Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For more information, please visit www.harpoontx.com.

Invus

Cormorant Asset Management

Commodore Capital

Ally Bridge Group

Soleus Capital

Surveyor Capital

K2 HealthVentures

Lion Point Capital

New Leaf Venture Partners

RA Capital Management

Ridgeback Capital

Arix Bioscience

Taiho Ventures

UBS Asset Management

Lilly Asia Ventures

MPM Capital

NS Investment

oncology impact fund

OrbiMed

Harpoon Therapeutics

Read more about our recent news in our press release here:  https://lnkd.in/d6KUfr3S

We are pleased to announce the promotion of Wendy Chang, GTML™ to Chief People Officer. Ms. Chang joined Harpoon in 2022 as Senior Vice President of Human Resources where she aligned Harpoon’s talent with our strong culture and patient-centric mission. Ms. Chang brings more than twenty years of human resources experience to the role. 

View Our Press Release: https://lnkd.in/eu3dHFGe  

$HARP #immunooncology #TCell #cancer # HPN217 #biotech

Harpoon to present updated interim results from the Phase 1/2 clinical trial of T Cell engager #HPN328 at American Society of Clinical Oncology (ASCO) - Genitourinary Cancers
 
 View full release here: https://lnkd.in/esvmmXBk 
 
#immunooncology #TCell #cancer #biotech #ASCOGU2024

Today we presented the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting and Exposition, and declared 12 mg as the HPN217 recommended Phase 2 dose
 
View full release here: https://lnkd.in/dbh3GJta
 
 $HARP #immunooncology #TCell #cancer #biotech #ASH2023 #RP2D

Now available: our third quarter 2023 financial results. Learn more about the results and highlights here: https://lnkd.in/gESeyRwi 
 
 $HARP #immunooncology #TCell #cancer #HPN217 #HPN328 #biotech #earnings #financialresults

Harpoon announced upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting and Exposition.
 
View full release here: https://lnkd.in/gh-bdiwt
 
 $HARP #immunooncology #TCell #cancer #biotech #ASH2023

Harpoon announced that it has entered into a securities purchase agreement for a #PIPE of up to $150M, led by leading biotechnology investors. 

View full release here: https://lnkd.in/gm-_ci7H

Management hosted a post-ESMO webcast and the replay is available now: https://lnkd.in/gSbKKsgp

#immunooncology #TCell #cancer #biotech #ESMO2023 #financing

Harpoon announced the updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer and other neuroendocrine tumor types in a poster at ESMO - European Society for Medical Oncology Congress 2023

View full announcement here: https://lnkd.in/gt9qhmWZ

Registration for Post-ESMO webcast here: https://lnkd.in/gSbKKsgp 

#immunooncology #TCell #cancer #biotech #ESMO2023

Join Harpoon management for a live webcast reviewing interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in #SCLC and #NEN presented at ESMO - European Society for Medical Oncology Congress 2023

Registration is open now: https://lnkd.in/gSbKKsgp 

View full release here: https://lnkd.in/gt9qhmWZ
 
$HARP #immunooncology #TCell #cancer #biotech #ESMO2023

Harpoon to present interim tolerability and response data from the Phase 1/2 clinical trial of T Cell engager #HPN328 at ESMO - European Society for Medical Oncology
 
View full release here: https://lnkd.in/gPRWbhsC 

$HARP #immunooncology #TCell #cancer #biotech #ESMO23

DNSSEC

Google Maps

IPv6

COVID-19

President and CEO

Jerry Mcmahon

Chief Medical Officer

Natalie Sacks

Vice President Protein Science

Bryan Lemon

Vice President, Development Operations and Project Management

Omer Siddiqui

SVP Business Development & Corporate Strategy

Rachael Lester

Sr Vice President, Human Resources

Wendy Chang

Associate Director, CMC Operations

Alpana Naresh

Sr. Director, Clinical Operations

Annie Winterhall

Controller

Frank Lanza

Senior Director Quality Assurance

George Tkhinvaleli

Ron Hunt

Mark Chin

Scott Myers

Luke Evnin

Jonathan Drachman

Patrick Baeuerle

Georgia Picht

Co-Founder

Julie Eastland

Chief Executive Officer

Luke Walker

Holger Wesche

SENIOR VICE PRESIDENT

Biotechnology Acquired Companies With More Than $10M in Revenue

Therapeutics Companies that Exited

Health Care Companies With More Than 10 Employees (Top 10K)

West Coast Acquired Companies With Fewer Than 1000 Employees (Top 10K)

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies.  Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Post-IPO Equity - Harpoon Therapeutics

Series C - Harpoon Therapeutics

Series B - Harpoon Therapeutics

Series A - Harpoon Therapeutics

South San Francisco

California

United States

North America

Merck closes $650M Harpoon acquisition

Harpoon Therapeutics stock ticks higher amid Nasdaq delisting notice for sale to Merck

Harpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to Merck

Harpoon Therapeutics ticks higher after HSR waiting period for Merck deal expires

Merck, Johnson & Johnson Announce Acquisitions to Bolster ...

Merck Is in Advanced Talks to Buy Cancer Drugmaker ...

Merck to acquire Harpoon Therapeutics for approximately $680m

A novel antibody-based drug discovery platform designed to enhance the patient's immune system's ability to target and kill cancer cells.

Ukraine

Europe

India

Asia

France

HTML5

GoDaddy Premium DNS

GoDaddy

Microsoft Outlook

jQuery

Google Maps API

Google Analytics

Google Fonts

Vimeo

Apache Server

Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines in areas of unmet medical need.

Gilead Sciences, Inc.

Bristol Myers Squibb is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases.

Bristol Myers Squibb

Amgen is a multinational biopharmaceutical company that focuses on the discovery, development, and delivery of innovative human therapeutics.

Amgen Inc.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company that develops a novel class of T cell engagers to harness the power of the body's immune system to treat cancer and other diseases.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

news impact assignment basic	general	Mar 5, 2024 11:16 AM	566318d9
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 11:16 AM	6a26d56f
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	64cf02eb
crunchbase profile	general	Nov 19, 2024 11:27 AM	95f6e5de
li profile	general	Mar 5, 2024 11:16 AM	0db156c9
translate crunchbase fundingrounds	general	Nov 19, 2024 1:16 PM	d0cbf382
peers	general
news basic	general	Mar 5, 2024 11:16 AM	fe271a71
bundesanzeiger	filings
financials download nd	financials
private financials	financials

HARP

COM:HARPOONTX

Harpoon Therapeutics, Inc.

Last Close

22.99

08/03 21:00

Market Cap

865.08M

Beta: -

Volume Today

6.40M

Avg: -